Over a mean follow-up of 3.9 years, GLP1 receptor agonist treatment was not associated with a substantially increased risk of thyroid cancer compared with dipeptidyl peptidase 4 (DPP4) inhibitors, and in an additional analysis, sodium-glucose cotransporter 2 inhibitors. This evidence concerns the gene SLC5A2 and thyroid gland carcinoma.